Kepler Capital Markets Analysts Give Roche (ROG) a CHF 226 Price Target

Roche (VTX:ROG) has been given a CHF 226 price objective by equities research analysts at Kepler Capital Markets in a report released on Wednesday. The brokerage presently has a “neutral” rating on the healthcare company’s stock. Kepler Capital Markets’ target price indicates a potential downside of 3.07% from the stock’s current price.

Several other equities analysts have also issued reports on the company. Goldman Sachs Group set a CHF 325 target price on Roche and gave the stock a “buy” rating in a research report on Thursday, September 21st. Jefferies Group set a CHF 290 target price on Roche and gave the stock a “buy” rating in a research report on Thursday, September 21st. JPMorgan Chase & Co. restated a “buy” rating on shares of Roche in a research report on Monday, September 25th. BNP Paribas set a CHF 235 target price on Roche and gave the stock a “sell” rating in a research report on Monday, September 25th. Finally, Deutsche Bank set a CHF 258 target price on Roche and gave the stock a “neutral” rating in a research report on Wednesday, October 4th. Four equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of CHF 258.95.

Shares of Roche (VTX:ROG) traded down CHF 2.85 during trading hours on Wednesday, reaching CHF 233.15. The company’s stock had a trading volume of 2,450,000 shares, compared to its average volume of 1,570,000. The company has a market cap of $201,050.00 and a PE ratio of 20.72. Roche has a 12-month low of CHF 226.10 and a 12-month high of CHF 273.

COPYRIGHT VIOLATION NOTICE: “Kepler Capital Markets Analysts Give Roche (ROG) a CHF 226 Price Target” was posted by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this piece of content on another site, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://stocknewstimes.com/2018/01/17/kepler-capital-markets-analysts-give-roche-rog-a-chf-226-price-target.html.

About Roche

Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.

Analyst Recommendations for Roche (VTX:ROG)

Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply